|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rapid generation of sustainable HER2-specific T cell immunity in HER2 breast cancer patients using a degenerate HLA class II epitope vaccine.
|
31757875 |
2020 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 21-gene recurrence score (RS) assay is prognostic among women with early-stage estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer and is used to inform recommendations for chemotherapy.
|
31809240 |
2020 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study investigated whether adding a taxane to an anthracycline-based regimen improved prognosis in node-positive, ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients in a real-world setting.
|
31327134 |
2020 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
|
31330065 |
2020 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The therapeutic HER2-targeting antibody trastuzumab has been shown to elicit tumor immune response in a subset of HER2-positive (HER2+) breast cancer.
|
31618954 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of the Trial Assigning IndividuaLized Options for Treatment (TAILORx) suggested that approximately 70% of T1-2N0M0, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients can avoid chemotherapy and receive only adjuvant endocrine therapy.
|
31809316 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>PIK3CA</i> mutations occur in approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
|
31091374 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Perturbation of pri-miR-515 results in the upregulation of HER2 protein levels, rendering HER2- breast cancer cells more sensitive to Herceptin treatment.
|
31122764 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the past four years, the CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, received their first FDA approval for the treatment of Hormone Receptor (HR)-positive and Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer after showing significant improvements in progression-free survival in the PALOMA-1, MONALEESA-2 and the MONARCH-2 randomized clinical trials, respectively.
|
30959874 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lapatinib, a reversible epidermal growth factor receptor (EGFR/ERBB1/HER1) and HER2 TKI, is used for the treatment of advanced HER2+ breast cancer in combination with capecitabine, in combination with trastuzumab in patients with hormone receptor-negative metastatic breast cancer, and in combination with an aromatase inhibitor for the first-line treatment of HER2+ breast cancer.
|
31141894 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alpelisib has demonstrated efficacy in combination with fulvestrant as treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer in patients with a PIK3CA mutation and was recently approved for this indication in the USA.
|
31256368 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neratinib, an irreversible inhibitor of HER1, HER2, and HER4, is Food and Drug Administration approved for the extended adjuvant treatment of stage I-III HER2+ BC to follow trastuzumab-based therapy.
|
30607980 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results show that complex <b>pnpRu-14</b> is much more effective in promoting in vitro cytotoxic effects on HER2+ and RH+/HER2- breast cancer than the reference metallodrugs cisplatin, carboplatin, or RAPTA-C.
|
31460427 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2-positive (HER2+) breast cancer (BC) affects older women nearly as frequently as younger ones.
|
31235436 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
An earlier analysis of this phase 3 trial showed that the addition of a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor to endocrine therapy provided a greater benefit with regard to progression-free survival than endocrine therapy alone in premenopausal or perimenopausal patients with advanced hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
|
31166679 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
OBJECTIVEWith increasing survival for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer in the trastuzumab era, there is an increased risk of brain metastasis.
|
30738402 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we hypothesize that a triple and sequential combination therapy of paclitaxel, a potent cytotoxic agent, before concomitant administration of dasatinib, a SRC proto-oncogene nonreceptor tyrosine kinase (Src) family kinase inhibitor, with everolimus, restores sensitivity to treatment in refractory HER2+ BC.
|
30898866 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current randomized, controlled, multicenter clinical trial was conducted to investigate the efficacy of concurrent neoadjuvant chemotherapy (NCT) and estrogen deprivation in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
|
30892700 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bevacizumab for human epidermal growth factor receptor 2 (HER2)-negative breast cancer was found to be associated with improved overall (hazard ratio, 0.69; 95% CI, 0.53-0.90) and disease-free survival (hazard ratio, 0.83; 95% CI, 0.67-1.03).
|
31337531 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g.
|
30922362 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The nanoMIPs, imprinted using HER2 N-glycans, could bind almost all HER2 glycans and suppress the dimerization of HER2 with other HER family members, blocking the downstream signaling pathways, thereby inhibiting HER2+ breast cancer growth.
|
31166063 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A systematic search of PubMed, EMBASE, The Cochrane Library and conference proceedings was carried out in order to identify the RCTs that investigated a standard versus a shorter duration of adjuvant trastuzumab in HER2+ BC patients.
|
30317424 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trastuzumab is a milestone in the treatment of human epidermal growth factor receptor 2 positive (HER2+) breast cancer (BC), in both the early and metastatic settings.
|
30781624 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The benefits of chemotherapy in node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients with the 21-gene recurrence score (RS) of 18-30, particularly those with RS 26-30, are not known.
|
31619259 |
2019 |
|
HER2-negative breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our search included randomized trials of adjuvant H plus chemotherapy for early-stage HER2+ BC, and excluding trials of neoadjuvant therapy or without data to obtain hazard ratios (HRs) for outcomes.
|
30242579 |
2019 |